Service Incident: New DOI registrations are working again. Re-registration of failed DOI registrations (~500) are still affected by the service incident at DataCite (our DOI registration agency).
Published March 25, 2020 | Version v1
Journal article Open

Impact of a Daily Probiotic (Lactobacillus casei Shirota) for 12 Months on the Frequency of Diverticulitis Episodes: Feasibility Study in Primary Care.

  • 1. 60 Manor Way, Onslow Village, Guildford, Surrey GU2 7RR, UK
  • 2. Department of Nutritional Sciences, Faculty of Health and Medical Sciences, Duke of Kent Building, University of Surrey, Guildford, Surrey GU2 7TE
  • 3. Queen's Avenue, Dorchester, DT1 2EP, formerly at Yakult UK Limited, Odyssey Business Park, West End Road, South Ruislip HA4 6QQ, UK
  • 4. Department of Clinical Medicine and Ageing, University of Surrey, Guildford, Surrey GU2 7XH, UK.
  • 5. Expert Nutrition Works, Whimple, Exeter, EX5 2PP
  • 6. Department of Mathematics, University of Surrey, Guildford, Surrey GU2 7XH, UK.
  • 7. Nutrition and Dietetic Service (Cambridge and Peterborough NHS Foundation Trust), First Floor, Sackville House, Sackville Way, Cambourne, Cambridgeshire, CB23 6HL

Description

Background:Some small secondary care studies have shown benefits from taking probiotics in diverticular disease. We investigated the feasibility of conducting a year-long probiotic study in primary care.

Methods:Patients (n=21) with a past history of uncomplicated acute diverticulitis but not currently taking antibiotics were recruited from four general practices. Subjects were asked to take the daily probiotic drink YakultÒ. Probiotic effects were assessed by comparing clinically diagnosed diverticulitis attacks in the 6 months prior to probiotic intervention with the 0-6 and 6-12 month periods after probiotic intervention commenced. Effects on gastrointestinal symptoms were assessed by validated questionnaires at baseline, 6 and 12 months. Diet diaries were also completed.

Results: Two thirds (14/21) of subjects who demonstrated good adherence in taking the daily probiotic improved symptomatically (p=0.025). Clinical presentations with diverticulitis were down 50% during the study period compared with the 12 months period before (7 vs 14 cases; p=0.021). The mean change in gastrointestinal symptom score improved significantly (p <0.001). Diverticulitis episodes did not correlate with body mass index (BMI), diabetic status or dietary fibre. 

Conclusions: Taking the daily probiotic was associated with a lower rate of clinical presentation with diverticulitis episodes and improvement in gastrointestinal symptoms. Sufficient information is presented to design a definitive trial. However, we recommend inclusion of a method to validate the diagnosis of diverticulitis. It is feasible to recruit and run a study that requires participants to take a daily probiotic drink for a year in a primary care setting.

LACTOPRoD was registered at ClinicalTrials.gov: NCT01609751 in 2012.

Files

ANPH-02-0016.pdf

Files (569.6 kB)

Name Size Download all
md5:38dd89f6fca6b5af6f2ae6c6a72e294a
569.6 kB Preview Download